168 related articles for article (PubMed ID: 17519066)
21. A phase I trial and pharmacokinetic study of tipifarnib, a farnesyltransferase inhibitor, and tamoxifen in metastatic breast cancer.
Lebowitz PF; Eng-Wong J; Widemann BC; Balis FM; Jayaprakash N; Chow C; Clark G; Gantz SB; Venzon D; Zujewski J
Clin Cancer Res; 2005 Feb; 11(3):1247-52. PubMed ID: 15709195
[TBL] [Abstract][Full Text] [Related]
22. Phase I study of combination therapy with S-1 and docetaxel (TXT) for advanced or recurrent gastric cancer.
Yoshida K; Hirabayashi N; Takiyama W; Ninomiya M; Takakura N; Sakamoto J; Nishiyama M; Toge T
Anticancer Res; 2004; 24(3b):1843-51. PubMed ID: 15274365
[TBL] [Abstract][Full Text] [Related]
23. Sequence effect of docetaxel and carboplatin on toxicity, tumor response and pharmacokinetics in non-small-cell lung cancer patients: a phase I study of two sequences.
Ando M; Saka H; Ando Y; Minami H; Kuzuya T; Yamamoto M; Watanabe A; Sakai S; Shimokata K; Hasegawa Y
Cancer Chemother Pharmacol; 2005 Jun; 55(6):552-8. PubMed ID: 15856233
[TBL] [Abstract][Full Text] [Related]
24. Phase I safety, pharmacokinetic and pharmacodynamic studies of 2-methoxyestradiol alone or in combination with docetaxel in patients with locally recurrent or metastatic breast cancer.
James J; Murry DJ; Treston AM; Storniolo AM; Sledge GW; Sidor C; Miller KD
Invest New Drugs; 2007 Feb; 25(1):41-8. PubMed ID: 16969706
[TBL] [Abstract][Full Text] [Related]
25. Phase I study of pulsatile 3-day administration of afatinib (BIBW 2992) in combination with docetaxel in advanced solid tumors.
Awada AH; Dumez H; Hendlisz A; Wolter P; Besse-Hammer T; Uttenreuther-Fischer M; Stopfer P; Fleischer F; Piccart M; Schöffski P
Invest New Drugs; 2013 Jun; 31(3):734-41. PubMed ID: 23161334
[TBL] [Abstract][Full Text] [Related]
26. Phase I study of docetaxel and topotecan in patients with solid tumors.
Tkaczuk KH; Zamboni WC; Tait NS; Meisenberg BR; Doyle LA; Edelman MJ; Hausner PF; Egorin MJ; Van Echo DA
Cancer Chemother Pharmacol; 2000; 46(6):442-8. PubMed ID: 11138457
[TBL] [Abstract][Full Text] [Related]
27. Phase 1 dose escalation and pharmacokinetic evaluation of oral gemcitabine prodrug (LY2334737) in combination with docetaxel in patients with advanced solid tumors.
Salazar R; Morales S; Gil-Martín M; Aguirre E; Oaknin A; Garcia M; Callies S; Wickremsinhe ER; Benhadji KA; Llombart A
Cancer Chemother Pharmacol; 2014 Jun; 73(6):1205-15. PubMed ID: 24744161
[TBL] [Abstract][Full Text] [Related]
28. A phase I and pharmacokinetic study of the combination of capecitabine and docetaxel in patients with advanced solid tumours.
Pronk LC; Vasey P; Sparreboom A; Reigner B; Planting AS; Gordon RJ; Osterwalder B; Verweij J; Twelves C
Br J Cancer; 2000 Jul; 83(1):22-9. PubMed ID: 10883663
[TBL] [Abstract][Full Text] [Related]
29. PR-104 a bioreductive pre-prodrug combined with gemcitabine or docetaxel in a phase Ib study of patients with advanced solid tumours.
McKeage MJ; Jameson MB; Ramanathan RK; Rajendran J; Gu Y; Wilson WR; Melink TJ; Tchekmedyian NS
BMC Cancer; 2012 Oct; 12():496. PubMed ID: 23098625
[TBL] [Abstract][Full Text] [Related]
30. Phase I study of docetaxel in combination with the P-glycoprotein inhibitor, zosuquidar, in resistant malignancies.
Fracasso PM; Goldstein LJ; de Alwis DP; Rader JS; Arquette MA; Goodner SA; Wright LP; Fears CL; Gazak RJ; Andre VA; Burgess MF; Slapak CA; Schellens JH
Clin Cancer Res; 2004 Nov; 10(21):7220-8. PubMed ID: 15534095
[TBL] [Abstract][Full Text] [Related]
31. A phase I and pharmacokinetic study of docetaxel combined with Doxil (pegylated liposomal doxorubicin) without and with granulocyte colony stimulating factor.
Pavlick AC; Chodkiewicz C; Liebes L; Hamilton A; Wasserheit C; Hochster H; Speyer J; Phillips Z; Downey A; Sorich J; Muggia F
Anticancer Drugs; 2004 Feb; 15(2):119-25. PubMed ID: 15075667
[TBL] [Abstract][Full Text] [Related]
32. Targeted inhibition of farnesyltransferase in locally advanced breast cancer: a phase I and II trial of tipifarnib plus dose-dense doxorubicin and cyclophosphamide.
Sparano JA; Moulder S; Kazi A; Vahdat L; Li T; Pellegrino C; Munster P; Malafa M; Lee D; Hoschander S; Hopkins U; Hershman D; Wright JJ; Sebti SM
J Clin Oncol; 2006 Jul; 24(19):3013-8. PubMed ID: 16769985
[TBL] [Abstract][Full Text] [Related]
33. A phase I clinical and pharmacokinetic study of oral CI-1033 in combination with docetaxel in patients with advanced solid tumors.
Garland LL; Hidalgo M; Mendelson DS; Ryan DP; Arun BK; Lovalvo JL; Eiseman IA; Olson SC; Lenehan PF; Eder JP
Clin Cancer Res; 2006 Jul; 12(14 Pt 1):4274-82. PubMed ID: 16857802
[TBL] [Abstract][Full Text] [Related]
34. A phase I study of MK-5108, an oral aurora a kinase inhibitor, administered both as monotherapy and in combination with docetaxel, in patients with advanced or refractory solid tumors.
Amin M; Minton SE; LoRusso PM; Krishnamurthi SS; Pickett CA; Lunceford J; Hille D; Mauro D; Stein MN; Wang-Gillam A; Trull L; Lockhart AC
Invest New Drugs; 2016 Feb; 34(1):84-95. PubMed ID: 26620496
[TBL] [Abstract][Full Text] [Related]
35. Docetaxel, ifosfamide and cisplatin in solid tumour treatment: a phase I study.
Specenier P; Rasschaert M; Van den Brande J; Dyck J; Schrijvers D; Huizing MT; Vermorken JB
Anticancer Drugs; 2010 Mar; 21(3):306-12. PubMed ID: 20087171
[TBL] [Abstract][Full Text] [Related]
36. Safety and tolerability of selumetinib as a monotherapy, or in combination with docetaxel as second-line therapy, in Japanese patients with advanced solid malignancies or non-small cell lung cancer.
Seto T; Hirai F; Saka H; Kogure Y; Yoh K; Niho S; Fukase K; Shimada H; Sasai M; Fukino K
Jpn J Clin Oncol; 2018 Jan; 48(1):31-42. PubMed ID: 29136201
[TBL] [Abstract][Full Text] [Related]
37. Phase I trial of bortezomib in combination with docetaxel in patients with advanced solid tumors.
Messersmith WA; Baker SD; Lassiter L; Sullivan RA; Dinh K; Almuete VI; Wright JJ; Donehower RC; Carducci MA; Armstrong DK
Clin Cancer Res; 2006 Feb; 12(4):1270-5. PubMed ID: 16489083
[TBL] [Abstract][Full Text] [Related]
38. Phase I and pharmacokinetic study of docetaxel and irinotecan in patients with advanced solid tumors.
Couteau C; Risse ML; Ducreux M; Lefresne-Soulas F; Riva A; Lebecq A; Ruffié P; Rougier P; Lokiec F; Bruno R; Armand JP
J Clin Oncol; 2000 Oct; 18(20):3545-52. PubMed ID: 11032597
[TBL] [Abstract][Full Text] [Related]
39. A phase I pharmacological and biological study of PI-88 and docetaxel in patients with advanced malignancies.
Chow LQ; Gustafson DL; O'Bryant CL; Gore L; Basche M; Holden SN; Morrow MC; Grolnic S; Creese BR; Roberts KL; Davis K; Addison R; Eckhardt SG
Cancer Chemother Pharmacol; 2008 Dec; 63(1):65-74. PubMed ID: 18320191
[TBL] [Abstract][Full Text] [Related]
40. Phase I trial of intraperitoneal docetaxel in the treatment of advanced malignancies primarily confined to the peritoneal cavity: dose-limiting toxicity and pharmacokinetics.
Morgan RJ; Doroshow JH; Synold T; Lim D; Shibata S; Margolin K; Schwarz R; Leong L; Somlo G; Twardowski P; Yen Y; Chow W; Lin P; Paz B; Chu D; Frankel P; Stalter S
Clin Cancer Res; 2003 Dec; 9(16 Pt 1):5896-901. PubMed ID: 14676112
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
